Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2297
mi
from 91732
Lake Worth, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Research and Treatment Center
2297
mi
from 91732
Lake Worth, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health / Stein Gerontological Institute
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2179
mi
from 91732
Orange City, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Medical Research Group of Central Florida
2179
mi
from 91732
Orange City, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2184
mi
from 91732
Orlando, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2135
mi
from 91732
Tampa, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Stedman Clinical Trials
2135
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
1712
mi
from 91732
Elk Grove Village, IL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Neuroscience Institute
1712
mi
from 91732
Elk Grove Village, IL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2402
mi
from 91732
Springfield, NJ
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
The Cognitive Research Center of New Jersey
2402
mi
from 91732
Springfield, NJ
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2101
mi
from 91732
Charlotte, NC
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
2101
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
24
mi
from 91732
Santa Ana, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
24
mi
from 91732
Santa Ana, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Columbus, GA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Medical Research and Health Education Foundation, Inc.
mi
from 91732
Columbus, GA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2040
mi
from 91732
Shaker Heights, OH
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Insight Clinical Trials
2040
mi
from 91732
Shaker Heights, OH
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
214
mi
from 91732
Fresno, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
214
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
46
mi
from 91732
Simi Valley, CA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Southern California Research, LLC
46
mi
from 91732
Simi Valley, CA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2319
mi
from 91732
Hallandale Beach, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
MD Clinical
2319
mi
from 91732
Hallandale Beach, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2313
mi
from 91732
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research
2313
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2315
mi
from 91732
Miami, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Miami Dade Medical Research Institute
2315
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
1810
mi
from 91732
Pensacola, FL
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Anchor Neuroscience
1810
mi
from 91732
Pensacola, FL
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2581
mi
from 91732
Quincy, MA
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Disease Center
2581
mi
from 91732
Quincy, MA
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
2444
mi
from 91732
White Plains, NY
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
The Burke Rehabilitation Hospital
2444
mi
from 91732
White Plains, NY
Click here to add this to my saved trials
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated:  12/31/1969
829
mi
from 91732
Portland, OR
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Enrolling
Updated: 12/31/1969
Memory Health Center at Summit Research Network
829
mi
from 91732
Portland, OR
Click here to add this to my saved trials
OCTA in Mild Cognitive Impairment and Alzheimer's Disease
Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography
Status: Enrolling
Updated:  12/31/1969
2203
mi
from 91732
Durham, NC
OCTA in Mild Cognitive Impairment and Alzheimer's Disease
Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Status: Enrolling
Updated:  12/31/1969
1332
mi
from 91732
Kansas City, KA
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
1332
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Partners at Meals - Respite Care and Home (PAM)
Mealtime Partnerships for People With Dementia in Respite Centers and at Home
Status: Enrolling
Updated:  12/31/1969
2184
mi
from 91732
Charleston, SC
Partners at Meals - Respite Care and Home (PAM)
Mealtime Partnerships for People With Dementia in Respite Centers and at Home
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients
Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress
Status: Enrolling
Updated:  12/31/1969
353
mi
from 91732
Scottsdale, AZ
Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients
Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress
Status: Enrolling
Updated: 12/31/1969
Perseverance Research Center
353
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
The Depression in Alzheimer's Disease Study (DIADS)
Status: Enrolling
Updated:  12/31/1969
2301
mi
from 91732
Baltimore, MD
The Depression in Alzheimer's Disease Study (DIADS)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Status: Enrolling
Updated:  12/31/1969
2199
mi
from 91732
Durham, NC
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics
Status: Enrolling
Updated: 12/31/1969
Durham VA
2199
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Music Therapy for Persons With Dementia
Music Therapy for Persons With Dementia: A Randomized Clinical Crossover Trial
Status: Enrolling
Updated:  12/31/1969
1527
mi
from 91732
Iowa City, IA
Music Therapy for Persons With Dementia
Music Therapy for Persons With Dementia: A Randomized Clinical Crossover Trial
Status: Enrolling
Updated: 12/31/1969
University of Iowa
1527
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
327
mi
from 91732
Palo Alto, CA
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto Health Care System
327
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Status: Enrolling
Updated:  12/31/1969
572
mi
from 91732
Salt Lake City, UT
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Status: Enrolling
Updated: 12/31/1969
Center for Alzheimer's Care, Imaging and Research
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
2485
mi
from 91732
New Haven, CT
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2485
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2281
mi
from 91732
Washington,
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Howard University
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2577
mi
from 91732
Boston, MA
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Boston University School of Medicine
2577
mi
from 91732
Boston, MA
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1932
mi
from 91732
Ann Arbor, MI
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2036
mi
from 91732
Cleveland, OH
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Risk Evaluation and Education for Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1757
mi
from 91732
Mobile, AL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
1757
mi
from 91732
Mobile, AL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1744
mi
from 91732
Northport, AL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
1744
mi
from 91732
Northport, AL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1459
mi
from 91732
Little Rock, AR
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
1459
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
73
mi
from 91732
Oceanside, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
73
mi
from 91732
Oceanside, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
100
mi
from 91732
San Diego, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
100
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
199
mi
from 91732
Santa Rosa, CA
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
199
mi
from 91732
Santa Rosa, CA
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
805
mi
from 91732
Pueblo, CO
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
805
mi
from 91732
Pueblo, CO
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Hockessin, DE
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from 91732
Hockessin, DE
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2140
mi
from 91732
Bradenton, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2140
mi
from 91732
Bradenton, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2126
mi
from 91732
Brooksville, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2126
mi
from 91732
Brooksville, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2117
mi
from 91732
Clearwater, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2117
mi
from 91732
Clearwater, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2188
mi
from 91732
Daytona Beach, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2188
mi
from 91732
Daytona Beach, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1852
mi
from 91732
Destin, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
1852
mi
from 91732
Destin, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
2205
mi
from 91732
Fort Myers, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
2205
mi
from 91732
Fort Myers, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
1844
mi
from 91732
Fort Walton Beach, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
1844
mi
from 91732
Fort Walton Beach, FL
Click here to add this to my saved trials
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Fruitland Park, FL
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from 91732
Fruitland Park, FL
Click here to add this to my saved trials